Denali Therapeutics Inc Dossier - Source-backed chat

Denali Therapeutics Inc

DNLINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.99

Intrinsic Value $11.84median of 2 methodsbased on filings through 30 Jun 2026

Market Price $20.53Price as of 1 Oct 2026

OvervaluedIntrinsic value is 42% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $3.3B

Enterprise Value $3.1B

Shares Outstanding 159.8M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Denali Therapeutics has successfully transitioned from a clinical-stage R&D entity to a commercial-stage biopharmaceutical company following the landmark FDA approval of AVLAYAH (tividenofusp alfa-eknm) for neurologic Hunter syndrome (MPS II). This approval serves as a critical clinical and regulatory validation of Denali's proprietary TransportVehicle (TV) platform, which is engineered to cross the blood-brain barrier (BBB). While the recent failure of the Phase 2b LUMA study of BIIB122 in idiopathic Parkinson's disease represents a setback, Denali's robust balance sheet—bolstered by a $195 million Priority Review Voucher sale and $200 million in synthetic royalty funding—provides a cash runway extending into 2028. This financial flexibility allows Denali to aggressively advance its deep pipeline of TV-enabled candidates targeting lysosomal storage disorders and neurodegenerative diseases.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets16 analysts · as of 18 Aug 2026

Low · most bearish analyst$27.00

Mean target$35.44

High · most bullish analyst$42.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$27.00

The commercial launch of AVLAYAH faces slower-than-expected adoption due to reimbursement hurdles or weight-based pricing complexities. Subsequent clinical readouts for DNL126 or DNL593 fail to show clear efficacy or biomarker engagement, raising doubts about the platform's scalability and forcing the company to seek highly dilutive financing as its cash runway shortens.

Base CaseCentral scenario

$35.44

Matches the consensus mean

AVLAYAH establishes a steady commercial footprint in the U.S. as a differentiated, brain-penetrant therapy for Hunter syndrome, with meaningful revenue inflection beginning in 2027. The company successfully navigates the independent development of DNL593 and the genetically targeted BEACON study for Parkinson's disease, maintaining its cash runway into 2028 without excessive dilution.

Bull CaseUpside scenario

$42.00

Rapid commercial uptake of AVLAYAH in the U.S. and successful expansion into Europe drive significant near-term revenue. Positive clinical readouts from the DNL126 program in Sanfilippo syndrome Type A and the DNL593 program in FTD-GRN by late 2026/2027 validate the platform's broad applicability, triggering new high-value pharmaceutical partnerships and accelerating the pipeline's development timeline.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-of-its-kind FDA-approved brain-penetrant enzyme replacement therapy (AVLAYAH) validating the proprietary TransportVehicle platform.
Strong liquidity position with approximately $1.05 billion in cash and marketable securities as of Q1 2026, further enhanced by a $195 million Priority Review Voucher sale in June 2026.
A highly diversified pipeline targeting high-unmet-need indications including Sanfilippo syndrome, Pompe disease, and frontotemporal dementia.

Key Investment Risks

Clinical development risk, as highlighted by the recent Phase 2b LUMA study failure of BIIB122 in idiopathic Parkinson's disease.
Commercial execution risk associated with launching a high-cost orphan drug (AVLAYAH) and securing favorable payer coverage.
Partnership volatility, exemplified by Takeda's strategic termination of the DNL593 co-development agreement.

Thesis Invalidation Triggers

Failure of the Phase 2/3 COMPASS confirmatory study to verify the clinical benefit of AVLAYAH, risking regulatory withdrawal.
Disappointing clinical data from the DNL126 Phase 1/2 study or the DNL593 program by the end of 2026.
A rapid, unexpected acceleration in cash burn that compromises the projected runway into 2028.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.